Matches in Wikidata for { <http://www.wikidata.org/entity/Q90068732> ?p ?o ?g. }
Showing items 1 to 72 of
72
with 100 items per page.
- Q90068732 description "artículu científicu espublizáu en xunu de 2017" @default.
- Q90068732 description "scientific article published on 01 June 2017" @default.
- Q90068732 description "wetenschappelijk artikel" @default.
- Q90068732 description "наукова стаття, опублікована в червні 2017" @default.
- Q90068732 name "Randomized phase III study of fluoropyrimidine (FP) plus bevacizumab (BEV) vs. FP plus irinotecan (IRI) and BEV as first-line therapy for metastatic colorectal cancer (mCRC): German AIO KRK0110 (ML22011)- study" @default.
- Q90068732 name "Randomized phase III study of fluoropyrimidine (FP) plus bevacizumab (BEV) vs. FP plus irinotecan (IRI) and BEV as first-line therapy for metastatic colorectal cancer (mCRC): German AIO KRK0110 (ML22011)- study" @default.
- Q90068732 type Item @default.
- Q90068732 label "Randomized phase III study of fluoropyrimidine (FP) plus bevacizumab (BEV) vs. FP plus irinotecan (IRI) and BEV as first-line therapy for metastatic colorectal cancer (mCRC): German AIO KRK0110 (ML22011)- study" @default.
- Q90068732 label "Randomized phase III study of fluoropyrimidine (FP) plus bevacizumab (BEV) vs. FP plus irinotecan (IRI) and BEV as first-line therapy for metastatic colorectal cancer (mCRC): German AIO KRK0110 (ML22011)- study" @default.
- Q90068732 prefLabel "Randomized phase III study of fluoropyrimidine (FP) plus bevacizumab (BEV) vs. FP plus irinotecan (IRI) and BEV as first-line therapy for metastatic colorectal cancer (mCRC): German AIO KRK0110 (ML22011)- study" @default.
- Q90068732 prefLabel "Randomized phase III study of fluoropyrimidine (FP) plus bevacizumab (BEV) vs. FP plus irinotecan (IRI) and BEV as first-line therapy for metastatic colorectal cancer (mCRC): German AIO KRK0110 (ML22011)- study" @default.
- Q90068732 P1433 Q90068732-4679E757-E0E8-41B8-B32F-A1D038748366 @default.
- Q90068732 P1476 Q90068732-2CB0D769-A1BE-48D4-95DB-A22B9B6D9D70 @default.
- Q90068732 P2093 Q90068732-02810C82-D6D7-4CE5-83E5-568F5F3FA6AF @default.
- Q90068732 P2093 Q90068732-06283255-5776-4BF8-96B3-E5B8136C660A @default.
- Q90068732 P2093 Q90068732-215FD320-961C-42FE-8F1B-88D2A5485CEE @default.
- Q90068732 P2093 Q90068732-286E2BF8-2C92-450F-AA26-3D03FA59A42E @default.
- Q90068732 P2093 Q90068732-31F1C343-34D4-4FF0-912B-921C837D3BAB @default.
- Q90068732 P2093 Q90068732-4B0C4CBF-F165-45D1-BF82-31CB125E1A52 @default.
- Q90068732 P2093 Q90068732-4B15CB8F-FC68-471C-991D-6A36FB704B4D @default.
- Q90068732 P2093 Q90068732-6E899D80-B6D6-49DF-AB4D-A35AC724E375 @default.
- Q90068732 P2093 Q90068732-759E8FC2-9DE6-4FBF-B02B-A8A9D6386E25 @default.
- Q90068732 P2093 Q90068732-7EEB3C84-1F70-4CC2-82CE-86FB10559273 @default.
- Q90068732 P2093 Q90068732-83B8F473-786C-4C3E-BB07-0522E349AB47 @default.
- Q90068732 P2093 Q90068732-A2C75332-BC0D-4EE7-8842-D6B24DAB8C24 @default.
- Q90068732 P2093 Q90068732-B8A63CAD-6793-4E24-AAC5-382FF4B4B206 @default.
- Q90068732 P2093 Q90068732-C3762CD7-C263-4997-9884-9644580E2875 @default.
- Q90068732 P2093 Q90068732-C4DE7946-5645-4751-A0ED-2148390585BB @default.
- Q90068732 P2093 Q90068732-EA6C30A8-16F5-4363-A3B7-84DE397E319F @default.
- Q90068732 P2093 Q90068732-F32614A8-7D5E-46F8-B839-663942FEFE17 @default.
- Q90068732 P2093 Q90068732-F4612866-0E92-4E2A-9CDF-4680E2FD6463 @default.
- Q90068732 P304 Q90068732-DF270C23-B11B-40B6-AC69-FFF356C7364A @default.
- Q90068732 P31 Q90068732-EF21A9DB-935C-4B4C-A7BF-CD4772F019D0 @default.
- Q90068732 P356 Q90068732-0D43BA20-C528-418D-BF17-5FF30967AFA8 @default.
- Q90068732 P478 Q90068732-AFE22060-4AEF-4062-91FC-8978E86CFE39 @default.
- Q90068732 P50 Q90068732-2AD14E1E-B1E6-407F-84B7-595771209323 @default.
- Q90068732 P577 Q90068732-5B735DE2-8D3C-41AE-B113-861F4271A149 @default.
- Q90068732 P921 Q90068732-02C1A34E-35AF-4712-9B47-20AA9F6F7AD5 @default.
- Q90068732 P921 Q90068732-3D116C19-8024-4224-BB19-3F38521D52DC @default.
- Q90068732 P921 Q90068732-401F9A0D-EBB1-4E60-AFC1-9D1230F5F3BF @default.
- Q90068732 P921 Q90068732-D1FC8313-A3E4-4F16-910B-660F339F0452 @default.
- Q90068732 P356 MDX262.025 @default.
- Q90068732 P1433 Q326122 @default.
- Q90068732 P1476 "Randomized phase III study of fluoropyrimidine (FP) plus bevacizumab (BEV) vs. FP plus irinotecan (IRI) and BEV as first-line therapy for metastatic colorectal cancer (mCRC): German AIO KRK0110 (ML22011)- study" @default.
- Q90068732 P2093 "Andreas Jung" @default.
- Q90068732 P2093 "Arndt Stahler" @default.
- Q90068732 P2093 "Bettina Peuser" @default.
- Q90068732 P2093 "Christina Peveling Genannt Reddemann" @default.
- Q90068732 P2093 "Claudio Denzlinger" @default.
- Q90068732 P2093 "Clemens Giessen-Jung" @default.
- Q90068732 P2093 "Dominik Modest" @default.
- Q90068732 P2093 "Gunter Schuch" @default.
- Q90068732 P2093 "Ingo Schwaner" @default.
- Q90068732 P2093 "Jens Freiberg-Richter" @default.
- Q90068732 P2093 "Jens Uhlig" @default.
- Q90068732 P2093 "Michael Schenk" @default.
- Q90068732 P2093 "Sebastian Stintzing" @default.
- Q90068732 P2093 "Swantje Held" @default.
- Q90068732 P2093 "Thomas Decker" @default.
- Q90068732 P2093 "Ullrich Graeven" @default.
- Q90068732 P2093 "Volker Heinemann" @default.
- Q90068732 P2093 "von Weikersthal Ludwig Fischer" @default.
- Q90068732 P304 "iii147-iii148" @default.
- Q90068732 P31 Q13442814 @default.
- Q90068732 P356 "10.1093/ANNONC/MDX262.025" @default.
- Q90068732 P478 "28 Suppl 3" @default.
- Q90068732 P50 Q47158556 @default.
- Q90068732 P577 "2017-06-01T00:00:00Z" @default.
- Q90068732 P921 Q108566365 @default.
- Q90068732 P921 Q188874 @default.
- Q90068732 P921 Q412197 @default.
- Q90068732 P921 Q413299 @default.